Shionogi Pill Prevents Covid in Household Exposure Study

Shionogi & Co.’s experimental Covid-19 pill cut the risk of infection among people exposed to the disease at home, according to a study that could revive interest in antivirals as a preventive tool.

In a late-stage trial of more than 2,000 household contacts, 2.9% of those given Shionogi’s once-daily pill ensitrelvir developed symptomatic Covid within 10 days, compared with 9.0% on placebo — a roughly two-thirds reduction in risk.